Antibiotic technology developed by a tenant of the Innovation Stockyard in the Kit Bond Science and Technology Incubator was purchased by a newly formed pharmaceutical company. Sopharmia, Inc., founded by Larry Sutton, MD, PhD, announced the closing of a $3.3 million Series A venture capital financing round and the formation of Gladius Pharmaceuticals Inc. based in Montreal. Sopharmia鈥檚 antibiotic technology is now wholly owned by Gladius Pharmaceuticals.
Sopharmia鈥檚 team, which did a large portion of their work at the campus鈥檚 Innovation Stockyard, pioneered dual mechanism small molecule antibiotics that combine antibiotic functionality with activity against one of the main causes of antibiotic resistance.
Although Sopharmia, Inc. 鈥済raduated鈥� from the Innovation Stockyard, Dr. Sutton and his team are orchestrating Gladius Pharmaceuticals鈥� North American research and development operations from their new company Sopharmbique LLC that will also be housed in the Innovation Stockyard.
鈥淭his financing enables us to accelerate the advancement of our lead compound,鈥� said Dr. Sutton. 鈥淚nnovation Stockyard has helped us through good times and bad. We鈥檙e pleased to continue this relationship with them.鈥�